

# IMLYGIC®

(talimogene laherparepvec)

This card format and content has been checked and approved by the Ministry of Health in June 2017

## IMLYGIC® PATIENT SAFETY INFORMATION CARD

---

IML-07-01-0818E August 2018 Version 1.0

**Instructions to provider:** A new card is to be completed with the first administration of Imlygic®. Record the batch number on this card for every administration of IMLYGIC®. If needed during treatment, please supply a new card to the patient.

Patient's Name: \_\_\_\_\_

IMLYGIC® Prescriber's (Doctor's) Name: \_\_\_\_\_

Doctor's Phone Number: \_\_\_\_\_

Name of Centre/Institution (if applicable): \_\_\_\_\_

Start Date of IMLYGIC® Treatment: \_\_\_\_\_

### IMLYGIC® Batch Numbers (Dates Administered):

_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Product manufacturer and license holder: Amgen Europe B.V.

IML-07-01-0818E August 2018 Version 1.0

IML-07-01-0818E August 2018 Version 1.0

# IMLYGIC®

## Information for patients:

Please carry this card with you at all times. Present this card to healthcare professionals (doctor, nurse) upon consultation or hospitalization.

If you or one of your close contacts develops a herpetic lesion (for example cold sore), please call the doctor (name and phone number provided above). The lesion can be tested to determine if it is caused by IMLYGIC®. IMLYGIC® is sensitive to the antiviral drug acyclovir and a possible infection can be treated with this drug as determined by your doctor. You can get more information from your IMLYGIC® patient and close contact educational brochure.

IML-07-01-0818E August 2018 Version 1.0

## Information for healthcare professionals, who are not the prescribers of IMLYGIC:

For full details of this product please refer to the physician leaflet:

[https://www.old.health.gov.il/units/pharmacy/trufot/Mucar\\_List.asp?p=1&Sr\\_Type=B\\_Rishaon&Y\\_Name=AMGEN EUROPE B.V.&Letter=Amgen&Y\\_Code=1031&safa=h](https://www.old.health.gov.il/units/pharmacy/trufot/Mucar_List.asp?p=1&Sr_Type=B_Rishaon&Y_Name=AMGEN EUROPE B.V.&Letter=Amgen&Y_Code=1031&safa=h)

- Should you have any questions or require additional information regarding the use of IMLYGIC®, please contact the local distributor Medison using following phone number: 03-9250215.
- In case of Herpes infection, please contact the local distributor Medison using phone number: 03-9250215.
- If you want more information you can request the IMLYGIC® health care provider brochure at Medison, the local distributor, using following phone number: 03-9250215.

**You can help by reporting any side effects you may get.** Adverse events can be reported to the Ministry of Health via the on-line form for adverse events reporting, that is located on the Ministry of Health home page [www.health.gov.il](http://www.health.gov.il) or by entering the link: <https://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il>. or report to local distributor Medison: [pv@Medison.co.il](mailto:pv@Medison.co.il)

IML-07-01-0818E August 2018 Version 1.0

IML-07-01-0818E August 2018 Version 1.0